» Articles » PMID: 22693587

Specific Recognition of P53 Tetramers by Peptides Derived from P53 Interacting Proteins

Overview
Journal PLoS One
Date 2012 Jun 14
PMID 22693587
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Oligomerization plays a major role in regulating the activity of many proteins, and in modulating their interactions. p53 is a homotetrameric transcription factor that has a pivotal role in tumor suppression. Its tetramerization domain is contained within its C-terminal domain, which is a site for numerous protein-protein interactions. Those can either depend on or regulate p53 oligomerization. Here we screened an array of peptides derived from proteins known to bind the tetrameric p53 C-terminal domain (p53CTD) and identified ten binding peptides. We quantitatively characterized their binding to p53CTD using fluorescence anisotropy. The peptides bound tetrameric p53CTD with micromolar affinities. Despite the high charge of the binding peptides, electrostatics contributed only mildly to the interactions. NMR studies indicated that the peptides bound p53CTD at defined sites. The most significant chemical shift deviations were observed for the peptides WS100B(81-92), which bound directly to the p53 tetramerization domain, and PKCα(281-295), which stabilized p53CTD in circular dichroism thermal denaturation studies. Using analytical ultracentrifugation, we found that several of the peptides bound preferentially to p53 tetramers. Our results indicate that the protein-protein interactions of p53 are dependent on the oligomerization state of p53. We conclude that peptides may be used to regulate the oligomerization of p53.

Citing Articles

Liquid-liquid phase separation in hepatocellular carcinoma.

Xu J, Liu W, Yao Y, Knowles T, Zhang Z, Zhang Y Front Cell Dev Biol. 2025; 12():1454587.

PMID: 39777266 PMC: 11703843. DOI: 10.3389/fcell.2024.1454587.


Long Non-Coding RNA MEG3 in Metal Carcinogenesis.

Zhang Z, Shi S, Li J, Costa M Toxics. 2023; 11(2).

PMID: 36851033 PMC: 9962265. DOI: 10.3390/toxics11020157.


p53: From Fundamental Biology to Clinical Applications in Cancer.

Capuozzo M, Santorsola M, Bocchetti M, Perri F, Cascella M, Granata V Biology (Basel). 2022; 11(9).

PMID: 36138802 PMC: 9495382. DOI: 10.3390/biology11091325.


Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.

Elwakeel A Front Cell Dev Biol. 2022; 10:879632.

PMID: 35493098 PMC: 9047732. DOI: 10.3389/fcell.2022.879632.


Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

Hernandez Borrero L, El-Deiry W Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556.

PMID: 33932560 PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556.


References
1.
Kaustov L, Lukin J, Lemak A, Duan S, Ho M, Doherty R . The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53. J Biol Chem. 2007; 282(15):11300-7. DOI: 10.1074/jbc.M611297200. View

2.
Rajagopalan S, Jaulent A, Wells M, Veprintsev D, Fersht A . 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res. 2008; 36(18):5983-91. PMC: 2566891. DOI: 10.1093/nar/gkn598. View

3.
Chen Y, Dey R, Chen L . Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure. 2010; 18(2):246-56. PMC: 2824536. DOI: 10.1016/j.str.2009.11.011. View

4.
Nikolaev A, Li M, Puskas N, Qin J, Gu W . Parc: a cytoplasmic anchor for p53. Cell. 2003; 112(1):29-40. DOI: 10.1016/s0092-8674(02)01255-2. View

5.
Hayouka Z, Hurevich M, Levin A, Benyamini H, Iosub A, Maes M . Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. Bioorg Med Chem. 2010; 18(23):8388-95. DOI: 10.1016/j.bmc.2010.09.046. View